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Establishing reliable prognostic factors as well as specific targets for new therapeutic
approaches is an urgent requirement in advanced ovarian cancer. For several tumor
entities, the ubiquitously spread scaffold protein β-arrestin 2, a multifunctional scaffold
protein regulating signal transduction and internalization of activated G protein-coupled
receptors (GPCRs), has been considered with rising interest for carcinogenesis.
Therefore, we aimed to elucidate the prognostic impact of β-arrestin 2 and its functional
role in ovarian cancer. β-arrestin 2 expression was analyzed in a subset of 156 samples
of ovarian cancer patients by immunohistochemistry. Cytoplasmic expression levels
were correlated with clinical as well as pathological characteristics and with prognosis.
The biologic impact of β-arrestin 2 on cell proliferation and survival was evaluated, in
vitro. Following transient transfection by increasing concentrations of plasmid encoding
β-arrestin 2, different cell lines were evaluated in cell viability and death. β-arrestin 2
was detected in all histological ovarian cancer subtypes with highest intensity in clear
cell histology. High β-arrestin 2 expression levels correlated with high-grade serous
histology and the expression of the gonadotropin receptors FSHR and LHCGR, as well
as the membrane estrogen receptor GPER and hCGβ. Higher cytoplasmic β-arrestin
2 expression was associated with a significantly impaired prognosis (median 29.88 vs.
50.64 months; P = 0.025). Clinical data were confirmed in transfected HEK293 cells,
human immortalized granulosa cell line (hGL5) and the ovarian cancer cell line A2780
in vitro, where the induction of β-arrestin 2 cDNA expression enhanced cell viability,
while the depletion of the molecule by siRNA resulted in cell death. Reflecting the role
of β-arrestin 2 in modulating GPCR-induced proliferative and anti-apoptotic signals, we
propose β-arrestin 2 as an important prognostic factor and also as a promising target for
new therapeutic approaches in advanced ovarian cancer.
Keywords: β-arrestin 2, ovarian cancer, immunohistochemistry, survival analysis, G protein-coupled receptor, in
vitro analyses
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INTRODUCTION
Epithelial ovarian cancer (EOC) is the most lethal gynecological
malignancy and is considered the fifth leading cause of
death among women (1), mainly due to late diagnosis in
advanced tumor stage leading to overall poor prognosis. Lack
of inadequate screening methods and rising resistances toward
chemotherapy over the clinical course further contribute to the
relatively low 5-years survival at around 45% (1, 2). Standard
treatment for advanced EOC consists of primary cytoreductive
surgery, followed by platinum-based combination chemotherapy
followed by targeted therapies like the anti-angiogenic antibody
bevacizumab or PARP inhibitors. To date, the most reliable
prognostic factors include volume of post-operative residual
disease, tumor stage diagnosed according to the International
Federation of Gynecology and Obstetrics (FIGO) staging system,
patient’s age and histology (2–7). EOCs are classified into four
histological subtypes: serous, mucinous, endometrioid, and clear-
cell, which vary in terms of phenotype, etiology and molecular
background (8). Taking the heterogeneity of ovarian cancer
into account appears crucial for developing new prognostic and
therapeutic strategies.
β-arrestin 2 is a multifunctional scaffold protein regulating
signal transduction and internalization of activated G protein-
coupled receptors (GPCRs) like follicle-stimulating hormone
receptor (FSHR) and luteinizing hormone/choriogonadotropin
receptor (LHCGR) by promoting clathrin-dependent
endocytosis (9). The β-arrestin family is a known activator
of signaling pathways involved in tumorgenesis (10–12) and
proliferation of certain tumor entities (13–17), including ovarian
cancer (18). Functional association between FSHR/LHCGR
and β-arrestin in granulosa cells could be demonstrated after
gonadotropin treatment in vitro (19, 20). In immortalized
ovarian cell lines, β-arrestin 2 triggers the activation of FSH-
induced mitogen-activated protein (MAP) kinase signaling
cascades linked to anti-apoptotic and proliferative events (21).
In this study, we aimed to evaluate the possible prognostic
impact of β-arrestin 2 on clinical course of ovarian cancer. The
role of β-arrestin 2 in modulating cell viability and survival
was elucidated by functional analyses in vitro, suggesting new
therapeutic approaches in ovarian cancer.
MATERIALS AND METHODS
Patients and Specimens
156 ovarian cancer samples of patients that underwent surgery
between 1990 and 2002 at the Department of Obstetrics
and Gynecology, Ludwig Maximilian University in Munich,
Germany, were analyzed (Table 1). The clinical data were
received from the patient’s charts, whereas the follow-up data
from the Munich Cancer Registry (MCR). Only patients with a
clear diagnosis of ovarian cancer and were included in this study,
while benign tumors, just as borderline tumors were excluded.
These patients had no history of previous or secondary cancers.
Also, none of the patients had neoadjuvant chemotherapy. After
the samples had been formalin-fixed and paraffin-embedded
(FFPE), they were evaluated by a specialized pathologist at the
TABLE 1 | Patient characteristics.
Parameters N Percentage (%)
HISTOLOGY
Serous 110 70.5





























≤60 years 83 53.2
>60 years 73 46.8
department of Pathology, Ludwig Maximilian University, who
classified them into histological subtypes [serous (n = 110),
endometrioid (n = 21), mucinous (n = 13), clear-cell (n = 12)]
and rated the tumor grading. The serous ovarian cancer samples
were divided into low and high grading. Endometrioid ovarian
cancer was graded according to G1–G3. For the mucinous
carcinoma, there is no WHO classification; however, the subtype
is often classified into G1–G3. The clear cell cancer was always
categorized as G3. Staging was performed using the FIGO
(WHO) and TNM classification. I (n = 35), II (n = 10,) III (n
= 103), and IV (n = 3). Data on primary tumor extension was
available in 155 cases: T1 (n = 40), T2 (n = 18), T3 (n = 93), T4
(n = 4), and on lymph node involvement in 95 cases: N0 (n =
43), N1 (n = 52). In nine cases available was the data on distant
metastasis: M0 (n= 3), M1 (n= 6).
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Ethical Approval
This study was approved by the Ethics Committee of the
Ludwig-Maximilians-University, Munich, Germany (approval
number 227-09 and 18-392). All tissue samples used for this
study were obtained from leftover material from the archives
of LMU Munich, Department Gynecology and Obstetrics,
Ludwig-Maximilians-University, Munich, Germany, initially
used for pathological diagnostics. The diagnostic procedures
were completed before the current study was performed. During
all experimental and statistical analysis, the observers were
fully blinded to patient’s data. All experiments were performed
according to the standards of the Declaration of Helsinki (1975).
As per declaration of our ethics committee no written informed
consent of the participants or permission to publish is needed
given the circumstances described above.
Immunohistochemistry
The formalin-fixed and paraffin-embedded ovarian cancer tissue
samples were dewaxed in xylene for 20min, before adding
100% ethanol to completely remove the Xylol. Unspecific color
responses were avoided by blocking the endogenous peroxidase
with 3% H2O2 in methanol (3ml 30% H2O2 + 97ml methanol),
followed by rehydrating it in 70%, then 50% ethanol. Afterwards
the slides were placed in a pressure cooker for 10min, using
sodium citrate buffer (pH = 6), made from 0.1M citric acid and
0.1M sodium citrate). After cooling down, this was followed by
washing the samples first in distilled water, then in phosphate
buffered saline (PBS) twice. After preprocessing, the slides were
incubated in a blocking solution (ZytoChem Plus HRP Polymer
System, Berlin, Germany, POLHRP-100) for 5min to prevent
an unspecific staining reaction. This was followed by a 16-
h incubation overnight at 4◦C with the primary antibodies:
anti-β-arrestin 2, rabbit IgG, polyclonal, Abcam, ab151774 at
a 1:1,500 dilution; anti-FSHR, rabbit IgG, polyclonal, Novus
Biologicals, NLS2231 at a 1:100 dilution, anti-LHCGR, rabbit
IgG, polyclonal, Acris, SP4594P at a 1:800 dilution; anti-GPER,
rabbit IgG, polyclonal, Lifespan Biosciences, LS92467 at a
1:600 dilution and anti-hCGβ, rabbit IgG, polyclonal, Dako,
A-0231 at a 1:300 dilution—then washed in PBS twice. Next
step was the application of reagent 2 (ZytoChem Plus HRP
Polymer System, Berlin, Germany, POLHRP-100), consisting of
a corresponding biotinylated secondary anti-rabbit IgG antibody
and the associated avidin-biotin-peroxidase complex, for 20min.
For the visualization reaction 3,3 Diaminobenzidine (DAB) and a
substrate buffer (Liquid DAB and Substrate Chromogen System,
Dako, Munich, Germany, K3468) was used for 30min, followed
by distilled water, to stop the reaction. After counterstaining
the slides with Mayer’s acidic hematoxylin (Waldeck-Chroma,
Münster, Germany, catalog-number 2E-038) for 2min, they
were dehydrated in an ascending series of alcohol (70, 96,
100%), brightened by adding xylol and then covered. Negative
and positive controls were used to assess the specificity of
the immunoreactions. Negative controls (colored in blue) were
performed in kidney, placental and uterine tissue by replacement
of the primary antibodies by species-specific (rabbit) isotype
control antibodies (Dako, Glostrup, Denmark). For positive
controls, placental and kidney tissues were used.
Staining Evaluation
All EOC specimens were examined with a Leitz
photomicroscope (Wetzlar, Germany) and specific β-arrestin 2
immunohistochemically staining reaction was observed in the
cytoplasm of the cells. The intensity and distribution pattern
of β-arrestin 2 staining was rated using the semi-quantitative
immunoreactive score (IR score, Remmele’s score). To obtain the
IR score result, the optional staining intensity (0= no, 1= weak,
2 = moderate, and 3 = strong staining) and the percentage of
positive stained cells (0 = no staining, 1 = <10% of the cells, 2
= 11–50% of the cells, 3 = 51–80% of the cells and 4 = >81%)
were multiplied. Cut-off points for the IR scores were selected
for the β-arrestin 2 staining considering the distribution pattern
of IR scores in the collective. β-arrestin 2 staining was regarded
as low with IRS 0–3 and as high with IRS ≥ 4. Renal biopsies
from patients with different ARRB2 expression levels served as
positive and negative control staining (22) (Figures 1E,F).
Cell Lines and Transfection Protocol
The immortalized human granulosa (hGL5) cell line of ovarian
origin (23), the human embryonic kidney (HEK293) and
the ovarian carcinoma (A2780) cell lines were used for
in vitro experiments. Cells were cultured and handled as
previously described (21, 24–26). hGL5 cells culture medium was
DMEM/F12 supplemented with 10% fetal bovine serum (FBS)
and 2mM L-glutamine (Sigma-Aldrich, St. Louis, MO, USA),
100 IU/mL penicillin and 50µg/mL streptomycin (Thermo
Fisher Scientific, Waltham, MA, USA) and 2% ITS + Premix
Universal Culture Supplement (#354352; Corning Incorporated,
Corning, NY, USA). TheHEK293 cell line was cultured inDMEM
additioned of 10% FBS, 2mM L-glutamine, 100 IU/mL penicillin
and 50µg/mL streptomycin. The A2780 cell line served as a
model of ovarian cancer and was cultured in RPMI1640 medium
(Sigma-Aldrich) additioned of 10% FBS, 1% Hepes (Sigma-
Aldrich), 2mML-glutamine, 100 IU/mL penicillin and 50µg/mL
streptomycin. Cell lines were maintained in an incubator at 37◦C
and 5% CO2.
The transfection protocol was described previously (25–28).
Briefly, 3.5 × 104 cells were transiently transfected in a 96-
well plate using increasing amount (range: 0–200 ng/well) of
β-arrestin 2-encoding pcDNA3.1 plasmid (29) or commercial
siRNA probes against β-arrestin 2 (#14387; Life-Technologies,
Carlsbad, CA, USA) (21), using an electroporator (Gene Pulser
MXcell; Bio-Rad Laboratories Inc., Hercules, CA, USA) in
accordance with established protocol and settings (21, 30).
Control probes without specific target mRNAs were loaded for
achieving equal amount of siRNA among wells.
Western Blot Analysis and Antibodies
Overexpression and knock-down of β-arrestin 2 and pro-
caspase 3 were evaluated by Western blotting, as previously
described (21, 24). Briefly, transfected cells were seeded in 24-
well plates (1 × 105 cells/well) and cultured 48 h before to
be lysed using 4◦C RIPA buffer. β-arrestin 2 and pro-caspase
3 were evaluated by 12% SDS-page and Western blotting,
using specific antibodies (#3857, Cell Signaling Technology Inc.,
Danvers, MA, USA; #MA1-91637, Thermo-Fisher Scientific,
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respectively). β-actin signals served as loading controls and
were detected using a horseradish peroxidase (HRP)-conjugated
specific antibody (#A3854; Sigma-Aldrich). Signals were revealed
by ECL chemiluminescent compound (GE HealthCare), after
incubation of the membranes with a secondary anti-rabbit HRP-
conjugated antibody (#NA9340V; GE HealthCare), except for β-
actin. Western blotting signals were acquired by the Quantity
One analysis software (Bio-Rad Laboratories Inc., Hercules,
CA, USA).
Analysis of Cell Viability and Death
hGLC, HEK293, and A2780 cells were seeded in 96-well plates
(1 × 104 cells/well) before viability assessment the by MTT
colorimetric assay (31), using a previously validated protocol
(21, 30). The absorbance was detected by a Victor3 plate reader
(Perkin Elmer Inc., Waltham, MA, USA). A measure of death
cells was obtained by incubating samples 30min with propidium
iodide (32). Cells were washed twice by PBS before excitation
and light emission detection by a CLARIOstar microplate
reader (BMG LabTech, Ortenberg, Germany), following the
manufacturer’s protocol. Data were represented as box and
whiskers plots in a graph, as a measure of cell viability,
and control of protein amount per well was performed by
Bradford assay.
Statistical Analysis
IBM SPSS Statistics, version 25.0 (IBM Corporation, Armonk,
NY, USA) was used for collecting and analyzing all the
data for statistical significance. Overall-survival was compared
with Kaplan-Meier curves and log-rank testing was used
to detect differences in patients’ overall survival times. The
Spearman correlation coefficient (cc) was used for detecting
correlations between immunohistochemical staining outcomes.
For multivariate analyses, the cox regression was performed.
Results obtained from cell lines were analyzed by D’Agostino
and Pearson normality test before applying the Kruskal-Wallis
test together with Dunn’s correction for multiple comparisons,
using the GraphPad Prism 6.0 software (GraphPad Software Inc.,
La Jolla, CA, USA). For all analysis a P-value of <0.05 was
considered to be statistically significant.
RESULTS
β-arrestin 2 Expression and the Correlation
to Clinical and Pathological Characteristics
The clinicopathologic characteristics of the analyzed ovarian
cancer patients are listed in Table 1. 104 (67%) out of 156
ovarian cancer specimens showed positive cytoplasmic β-arrestin
2 expression. The median immunoreactive score (IRS) of
cytoplasm staining was 2 (with a range of 0–12). Clear cell
histology exhibited the strongest β-arrestin 2 staining (Kruskal-
Wallis test; p = 0.01) when compared with different histological
subtypes (Figures 1A–D).
Representative staining of benign ovarian and fallopian tube
tissue show positive results in epithelial cells, granulosa cells and
theca cells. The ovarian and fallopian tube stroma did not show a
β-arrestin 2 staining (Figures 2A,B).
We analyzed the correlation between β-arrestin 2 and
clinicopathological data, such as histology, grading, and FIGO
classification (Table 2). A positive correlation was observed
between high β-arrestin 2 expression and high-grade serous
histology (Spearman’s correlation analysis; p= 0.041; cc= 0.169).
Moreover, no other correlations were observed.
β-arrestin 2 Correlates With Gonadotropin
Receptors Expression
We then analyzed the correlation between β-arrestin 2 expression
and other parameters previously examined (33–37) in the same
ovarian cancer cohort (Table 3). A positive correlation was
detected to the expression of the gonadotropin receptors FSHR
(p= 0.029; cc= 0.183) and LHCGR (p= 0.001; cc= 0.284), the G
protein-coupled membrane estrogen receptor GPER (p= 0.0009;
cc = 0.215) as well as with the choriogonadotropin beta subunit
(hCGβ) (p < 0.001; cc = 0.36). Representative stainings of the
correlated parameters are shown in Supplementary Figure 1.
High β-arrestin 2 Expression Is Associated
With Impaired Overall Survival
Age of the patient cohort was 58.7 ± 31.4 years (median ±
standard deviation, SD; n = 156) with a range of 31–88 years.
The overall survival of the EOC patients was 34.4± 57.8 months
(median ± SD; n = 156). High β-arrestin 2 expression (IRS 4–
12) is associated with shorter overall survival. As depicted on the
Kaplan-Meier curve, higher cytoplasmic β-arrestin 2 expression
correlates with a significantly impaired prognosis (Figure 3;
50.64 vs. 29.88 months, median; p= 0.025).
Clinicopathological Parameters as
Independent Prognostic Factors
A multivariate cox-regression analysis was performed to detect
which parameters were independent prognostic factors for
overall survival in the present cohort. In this analysis, patients’
age (p = 0.014) and FIGO stage (p < 0.001) were independent
factors for overall survival. High β-arrestin 2 (p = 0.152),
however, was not confirmed as an independent factor of
prognostic independence (Table 4).
Effects of β-arrestin 2 Overexpression and
Depletion on Cell Viability
Since β-arrestin 2 expression levels were found to correlate with
overall survival of ovarian cancer patients, the impact of the
molecule on cell proliferation and survival was evaluated, in vitro.
Cell viability and death are represented by box and whiskers plots
(Figure 4).
Western blot analysis demonstrated that β-arrestin 2
expression levels increase together with the amount of cDNA
encoding the molecule, in the HEK293, hGL5 and A2780 cell
lines (Figure 4A). We found increased viability of all cell models
overexpressing β-arrestin 2, compared to mock-transfected cells
used as controls (Figures 4B–D; Kruskal-Wallis test; p < 0.01;
n = 8). Moreover, highest levels of cell viability corresponded
to the highest amount of plasmid transfected. These results are
corroborated by data from propidium iodide-stained HEK293
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FIGURE 1 | Detection of β-arrestin 2 with immunohistochemistry. (A) Cytoplasmic β-arrestin 2 staining in ovarian cancer with serous, (B) clear cell, (C) endometrioid,
and (D) mucinous histology. (E) β-arrestin 2 negative control (F) and positive control in human kidney tissue. Clear cell histology exhibited the strongest cytoplasmic
β-arrestin 2 expression (Kruskal-Wallis test; p = 0.01) when compared with different histological subtypes. Arrows demonstrate representatively β-arrestin 2 stained
cells. Images representative of three independent experiments.
and A2780 cells overexpressing β-arrestin 2, indicating that the
least cell death occurs with the highest amounts of β-arrestin
2-encoding plasmid transfected (Figures 4E–G; Kruskal-Wallis
test; p < 0.01; n = 8). However, data from transfected hGL5 cells
did not reveal any association between β-arrestin 2 expression
and cell death (Figure 4F; Kruskal-Wallis test; p ≥ 0.05; n= 8).
Since a positive correlation between β-arrestin 2 expression
and cell viability was found (Figure 4), control experiments were
performed by evaluating the cell viability and death of cells
maintained under β-arrestin 2 depletion, in vitro. Therefore,
HEK293, hGL5, and A2780 cells were treated by increasing
concentrations of siRNA probes silencing the endogenous
molecule, then MTT assay and propidium iodide staining were
performed (Figure 5).
The viability of all the cell lines is significantly reduced upon
β-arrestin 2 depletion (Figures 5A–C; Kruskal-Wallis test; p <
0.05; n = 8). These data are reflected by increased propidium
iodide signals occurring together with increasing amounts of
siRNAs, in HEK293 cells (Figure 5D; Kruskal-Wallis test; p <
0.05; n = 8), while similar signals were found between siRNA-
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FIGURE 2 | Detection of β-arrestin 2 with immunohistochemistry in benign ovary and fallopian tube. Detection of β-arrestin 2 with immunohistochemistry in benign
ovary (A) and fallopian tube (B). Positive β-arrestin 2 staining was observed in epithelial cells, granulosa cells and theca cells. The ovarian and fallopian tube stroma
did not show a β-arrestin 2 staining. Arrows demonstrate representatively β-arrestin 2 stained cells. Images representative of three independent experiments.
TABLE 2 | Correlation analysis between β-arrestin 2 expression and
clinicopathological data.
Variable P Correlation coefficient
Histology 0.075 −0.083
FIGO stage 0.673 0.086
Age 0.206 0.105
GRADING
Clear cell, endometrioid, and mucinous (G1–G3) 0.520 −0.088
Serous—low grading 0.052 −0.160
Serous—high grading 0.041* 0.169
Clinicopathologic data and β-arrestin 2 expresssion were correlated to each other using
Spearman’s correlation analysis. Significant correlations are indicated by asterisks (*p <
0.05). p, two-tailed significance.
and mock-treated hGL5 and A2780 cells (Figures 5E,F; Kruskal-
Wallis test; p≥ 0.05; n= 8). Western blotting analysis confirmed
the siRNA-dependence of β-arrestin 2 silencing, which is linked
to pro-caspase 3 cleavage in all the cell lines (Figure 5G).
DISCUSSION
Our study revealed for the first time that β-arrestin 2 expression
significantly correlates with impaired overall survival of ovarian
cancer patients and these results are consistent with the
proliferative role of β-arrestin 2 demonstrated in vitro. β-
arrestins are known to act as scaffold proteins controlling
multiple cellular functions, such as MAP kinase signaling,
GPCR trafficking and transcriptional modulations (38, 39).
Several studies demonstrated that β-arrestins are involved in
carcinogenesis of the ovary (11, 18) and other types of cancer
(10, 12–17). The relevance of the GPCR/β-arrestin pathway
in ovarian cancer cells is demonstrated by the finding that
endothelin-1 receptor/β-arrestin complex activates beta-catenin
signaling pathways with impact on carcinogenesis and metastatic
progression (11). Nevertheless, conflicting results have been
TABLE 3 | Correlation analysis of β-arrestin 2.
Staining β-arrestin 2 FSHR LHCGR GPER hCGβ
β-ARRESTIN 2
cc 1.000 0.183 0.284 0.215 0.360
p – 0.029 0.001 0.009 0.000
n 148 143 146 148 137
FSHR
cc 0.183 1.000 0.164 0.214 0.082
p 0.029 – 0.046 0.009 0.340
n 143 151 149 148 137
LHCGR
cc 0.284 0.164 1.000 0.170 0.200
p 0.001 0.046 – 0.037 0.018
n 146 149 154 151 140
GPER
cc 0.215 0.214 0.170 1.000 0.114
p 0.009 0.009 0.037 – 0.179
n 148 148 151 153 141
hCGβ
cc 0.360 0.082 0.200 0.114 1.000
p 0.000 0.340 0.018 0.179 –
n 137 137 140 141 142
cc, correlation coefficient; p, two-tailed significance; n, number of patients.
reported with a positive impact of angiotensin-mediated β-
arrestin expression in a clinical-genomic dataset from 820
ovarian cancer patients (40). Indicative results may be provided
by the analysis of gene expression data stored in public cancer
repositories. For instance, The Human Protein Atlas database
(https://www.proteinatlas.org; last accession: 03 March 2020)
revealed that β-arrestin 2-encoding gene (ARRB2) expression is
an unfavorable prognostic marker of prostate cancer, although
the association is not replicated for ovarian cancer. These
data corroborate, at least in part, our finding although they
should be considered cautiously, since gene expression levels
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FIGURE 3 | Kaplan–Meier estimate of β-arrestin 2. β-arrestin 2 expression (IRS 4–12) was associated with impaired overall survival (50.64 vs. 29.88 months, median;
p = 0.025). Censoring events have been marked in the graphs.
TABLE 4 | Multivariate analysis of the analyzed ovarian cancer patients (n = 156).
Covariate Coefficient (bi) [HR Exp (bi)] 95% CI P-value
Lower Upper
Patient’s Age (≤60 vs. >60) 0.625 1.869 1.133 3.084 0.014
FIGO (I, II vs. III, IV) 0.813 2.255 1.499 3.393 <0.001
GRADING
Clear cell, endometrioid, and mucinous (G1–G3) 0.142 1.153 0.749 1.774 0.517
Serous—low grading −0.695 0.499 0.160 1.562 0.232
Serous—high grading 0.654 1.924 0.765 4.838 0.164
High β-arrestin 2 −0.097 0.907 0.795 1.036 0.152
are not necessarily corresponding to protein levels and the
database does not allow to analyze all the specific histological
tumor subtypes.
The link between GPCR/β-arrestins complexes and cancer
is an established concept (41) and seems to be result of
sustained intracellular signaling occurring upon dysregulation
of intracellular β-arrestin protein levels (42). These molecules
were associated with drug resistance of breast (43) and lung
cancer cells (44), cancer cell migration and invasion (45),
tumor progression (46) and metastasis (47), as well as a
number of other tumors (48). Thus, β-arrestins were proposed
as a target for therapeutic strategies (49). Our data in vitro
confirm the proliferative role of β-arrestin 2 also in an ovarian
cancer cell line, as well as in hGL5 and HEK293 cells. There
are converging evidences that β-arrestin 2 depletion leads to
decreasing cell viability and/or activating a caspase 3-mediated
cell death, at least in HEK293 cells and confirmed in the
ovarian cancer cell line A2780. Interestingly, in hGL5 cells,
increased β-arrestin 2 expression is linked with upregulation of
cell viability, while the depletion of this molecule by siRNA did
not result in cell death. This is likely due to the integration
of exogenous E6 and E7 oncogenes in the hGL5 cell line
genome (23), which served for immortalizing them and, likely,
results in increased resistance to caspase 3 activation. On
the other hand, these oncogenes encode proteins inhibiting
tumor protein 53 (p53) and retinoblastoma (Rb) molecules
and interfering with apoptosis and cell cycle blockade. hGL5
have characteristics reflecting epithelial tumor cells, such as
fibroblast-like spindle shape and relatively high proliferation
rate, a feature depending on β-arrestins functioning (21), as
well as in other ovarian cancer cell lines (40). However, these
results underline that β-arrestins are modulators of proliferative
signals exerted through a molecular signaling module with
GPCRs and the extracellular-regulated MAP kinases 1 and
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FIGURE 4 | Evaluation of cell viability and death under 48-h β-arrestin 2 overexpression. HEK293, hGL5, and A2780 cells were transfected by increasing amount of
plasmid encoding β-arrestin 2 and cell viability and death were assessed by MTT and propidium iodide, respectively. Total protein content from 0.5 × 104 70%
confluent log phase cells were loaded. (A) Representative image of β-arrestin 2 detected in cell lysates by Western blotting using a specific rabbit antibody using
β-actin as a normalizer. (B) Box and Whiskers plot of MTT data, collected from transfected HEK293 cells overexpressing increasing levels of β-arrestin 2, representing
cell viability. (C) hGL5 cell viability evaluated by MTT. (D) β-arrestin 2-dependent cell viability of the A2780 ovarian cancer cell line. (E) Data from the β-arrestin
2-overexpressing HEK293, representing cell death, in propidium iodide-stained samples. (F) β-arrestin 2-overexpressing hGL5 cell death. (G) β-arrestin
2-overexpressing A2780 ovarian cancer cell death. Brightness/contrast of Western blotting pictures were adjusted uniformly in all panels. Asterisks indicate
significantly different data distribution than mock-transfected (untransfected) cells (Kruskal-Wallis test and Dunn’s correction for multiple comparisons; *P < 0.05; **P
< 0.001; ***P < 0.0001; n = 8).
2 (ERK1/2), in a number of cells (50), including ovarian
cells (21). Gonadotropin receptors are expressed in ovarian
cells and targeted by β-arrestin 2 (51). It is well-known that
gonadotropin receptor expression is dysregulated in ovarian
cancer (34, 36, 52) as well adrenal tumor (53), although the
specific influence of these receptor on carcinogenesis is still not
determined (54). One reason for this, may be the bi-directional
regulation of pro- and anti-apoptotic signals which depend on
FSHR and LHCGR expression levels (55). Interestingly, the
depletion of β-arrestin 2 may be linked to increased tumor
cell growth and angiogenesis, at least in certain cases, such
as lung cancer (56). In this case, the absence of β-arrestin 2
would lead to uncontrolled activation of proliferative signals
induced by other GPCRs, e.g., the interleukin 8 receptor
beta (CXCR2). Taken together, we could speculate that β-
arrestins may positively or negatively impact proliferative events,
modulating the activity of various GPCRs specifically expressed
in the tumor cells.
In correlation analyses, a link between β-arrestin 2 and the
G-protein coupled estrogen receptor (GPER) was identified.
This receptor is known for rapidly mediating non-genomic
signals induced by estrogens and was found in both healthy
and neoplastic human tissue (57, 58). Indeed, previous studies
revealed that GPER is related to better overall survival in ovarian
cancer patients (34, 59, 60). Since GPER belongs to the GPCRs
family, we may suppose that β-arrestin 2 might interact with
this membrane estrogen receptor and influence its physiological
function. However, this issue must be further investigated
because GPER recycling and intracellular trafficking seems to be
regulated by mechanisms not involving β-arrestins (61).
Interestingly, we also found an association between β-arrestin
2 and one of the two LHCGR ligands, hCGβ. This hormone
was shown to be associated with an increased 5-years survival
in LHCGR positive/FSHR negative ovarian cancer cases (33).
Although this study had limitations related to low specificity
of the anti-gonadotropin receptor antibodies employed (62),
it suggests that hCGβ and its receptor might be linked to
survival in these patients. These data would be in line with
the relatively high potency of hCGβ in inducing LHCGR-
mediated intracellular cAMP increase (27), as an effect linked
to the steroidogenic potential of the hormone and to pro-
apoptotic effects (24). On the other hand, these data would
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FIGURE 5 | Viability and death of 48-h β-arrestin 2-silenced HEK293, hGL5, and A2780 cells. Samples were transfected by increasing amount of siRNA probes
targeting the β-arrestin 2 mRNA and 48-h cell viability and death were assessed by MTT and propidium iodide. Total protein content from 3 × 104 70% confluent log
phase cells were loaded. (A) Box and Whiskers plot representing the HEK293 cell viability under β-arrestin 2 depletion. (B) β-arrestin 2-silenced hGL5 cell viability. (C)
β-arrestin 2-silenced A2780 ovarian cancer cell viability. (D) Data from the β-arrestin 2-silenced HEK293, representing cell death evaluated using propidium iodide
staining. (E) hGL5 cell death evaluated by propidium iodide. (F) Cell death in β-arrestin 2-silenced A2780 evaluated by propidium iodide. (G) Representative Western
blotting images demonstrating β-arrestin 2 depletion and pro-caspase 3 cleavage in HEK293, hGL5, and A2780 cell lysates. β-actin was the normalizer.
Brightness/contrast of Western blotting pictures were adjusted uniformly in all panels. Significantly different data distribution than mock-transfected (untransfected)
cells were indicated by asterisks. Kruskal-Wallis test and Dunn’s correction for multiple comparisons; *P < 0.05; **P < 0.001; ***P < 0.0001; n = 8).
be in contrast with the fact that hCGβ has been used as
a marker of certain tumors, such as the choriocarcinoma
(63), which reflects the involvement of β-arrestin 2 in the
hCGβ-mediated intracellular signaling (29) and suggests that
the connection between the two molecules in cancer merits
further investigations.
β-arrestin 2 is associated with a significantly impaired overall
survival of ovarian cancer patients. This finding is supported
by in vitro data demonstrating that β-arrestin 2 upregulates
the viability of an ovarian cancer cell line, and transfected
HEK293 and hGL5 cells. Reflecting the role of β-arrestins as
scaffold proteins linked to the GPCRs activity, correlations
between the β-arrestin 2 and FSHR and LHCGR expression
was identified ovarian cancer tissue. Taken together, we indicate
that β-arrestin 2 may be a promising new target in ovarian
cancer so that clinical implications should be further addressed in
future research.
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